Company research
STAAR SURGICAL CO
CIK 718937Updated Sep 27, 2026
SecuritySTAA · NASDAQ · equity
Name history
STAAR SURGICAL COMPANY · through Aug 17, 2004
STAA price & chart
Loading TradingView…
NASDAQ:STAA on TradingView ↗About the company
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the Company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.discoverICL.com. To learn more about STAAR, visit www.staar.com.
In the news
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, BTBD, CIO on Behalf of Shareholders News provided by Halper Sadeh LLP Oct 03, 2025, 11:04 ET Share this article Share to X Share this article Share to X NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law fir ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
4 filing
4 filing
4 filing
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 451,678,000Source | 509,524,000Source | 488,692,000Source | 414,898,000Source |
| Property, Plant and Equipment, NetUSD | 73,323,000Source | 84,889,000Source | 66,835,000Source | 50,921,000Source |
| GoodwillUSD | 1,786,000Source | 1,786,000Source | 1,786,000Source | 1,786,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | 173,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 153,150,000Source | 144,159,000Source | 183,038,000Source | 86,480,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 50,064,000Source | 77,897,000Source | 94,704,000Source | 62,447,000Source |
| Assets, CurrentUSD | 311,545,000Source | 367,940,000Source | 365,269,000Source | 311,723,000Source |
| Operating Lease, Right-of-Use AssetUSD | 29,609,000Source | 36,850,000Source | 34,387,000Source | 30,270,000Source |
| Other Assets, NoncurrentUSD | 1,350,000Source | 17,234,000Source | 3,339,000Source | 957,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 107,494,000Source | 112,189,000Source | 102,738,000Source | 82,706,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 498,000Source | 493,000Source | 488,000Source | 482,000Source |
| Retained Earnings (Accumulated Deficit)USD | -148,024,000Source | -67,576,000Source | -47,368,000Source | -72,635,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,511,000Source | -7,031,000Source | -4,113,000Source | 156,000Source |
| Stockholders' Equity Attributable to ParentUSD | 344,184,000Source | 397,335,000Source | 385,954,000Source | 332,192,000Source |
| Additional Paid in Capital, Common StockUSD | 504,682,000Source | 471,449,000Source | 436,947,000Source | 404,189,000Source |
| Liabilities and EquityUSD | 451,678,000Source | 509,524,000Source | 488,692,000Source | 414,898,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 68,504,000Source | 70,306,000Source | 65,036,000Source | 51,716,000Source |
| Operating Lease, Liability, CurrentUSD | 5,872,000Source | 3,894,000Source | 4,202,000Source | 3,524,000Source |
| Accounts Payable, CurrentUSD | 11,574,000Source | 16,704,000Source | 13,557,000Source | 11,576,000Source |
| Operating Lease, Liability, NoncurrentUSD | 32,481,000Source | 34,807,000Source | 31,425,000Source | 27,136,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 297,000Source | 1,077,000Source | 1,489,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 9,941,000Source | 13,363,000Source | 12,124,000Source | 9,787,000Source |
| Short-term InvestmentsUSD | 34,386,000Source | 86,335,000Source | 37,688,000Source | 125,159,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 30,588,000Source | 27,210,000Source | 23,516,000Source | 20,371,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -27,834,000Source | -16,493,000Source | 32,760,000Source | 19,601,000Source |
| Increase (Decrease) in InventoriesUSD | 16,981,000Source | 10,000,000Source | 14,361,000Source | 7,943,000Source |
| Increase (Decrease) in Accounts PayableUSD | -5,507,000Source | 75,000Source | -701,000Source | 1,805,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,916,000Source | 3,590,000Source | 3,264,000Source | -1,344,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -34,230,000Source | 15,725,000Source | 14,594,000Source | 35,715,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 46,339,000Source | -59,217,000Source | 74,347,000Source | -156,376,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,820,000Source | 23,394,000Source | 18,188,000Source | 18,108,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,520,000Source | 1,505,000Source | 2,097,000Source | — |
| Payments for Repurchase of Common StockUSD | 6,461,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -4,555,000Source | 5,724,000Source | 7,415,000Source | 8,297,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,991,000Source | -38,879,000Source | 96,558,000Source | -113,226,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 153,150,000Source | 144,159,000Source | 183,038,000Source | 86,480,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 7,830,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,437,000Source | -1,111,000Source | 202,000Source | -862,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 30,588,000Source | 27,210,000Source | 23,516,000Source | 20,371,000Source |
| Amortization of Intangible AssetsUSD | — | — | 13,000Source | 28,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | — | 47,000Source |
| Capitalized Computer Software, AmortizationUSD | 409,000Source | 0Source | 0Source | — |
| DepreciationUSD | 8,319,000Source | 6,891,000Source | 5,111,000Source | 4,481,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,603,000Source | -3,675,000Source | -1,909,000Source | -1,707,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -74,000Source | -1,694,000Source | -73,000Source | -65,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | 1,458,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 74,000Source | 1,694,000Source | 73,000Source | 65,000Source |
| General and Administrative ExpenseUSD | 85,783,000Source | 89,898,000Source | 72,319,000Source | 54,742,000Source |
| GoodwillUSD | 1,786,000Source | 1,786,000Source | 1,786,000Source | 1,786,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 154,000Source | — |
| Income Tax Expense (Benefit)USD | -1,815,000Source | 11,156,000Source | 12,349,000Source | 6,797,000Source |
| Inventory Write-downUSD | 5,334,000Source | 2,782,000Source | 4,851,000Source | 2,423,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -80,448,000Source | -20,208,000Source | 21,347,000Source | 38,755,000Source |
| Nonoperating Income (Expense)USD | 9,450,000Source | 3,559,000Source | 5,599,000Source | 1,750,000Source |
| Operating Lease, ExpenseUSD | 3,570,000Source | — | — | — |
| Operating Lease, Impairment LossUSD | 4,894,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 2,253,000Source | 815,000Source | 448,000Source | 205,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 124,145,000Source | 43,103,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 3,465,000Source | 7,392,000Source | 9,672,000Source | 8,422,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | 28,632,000Source | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 31,290,000Source | 28,618,000Source | 25,188,000Source | 22,252,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 239,442,000Source | 313,901,000Source | 322,415,000Source | 284,391,000Source |
| Cost of RevenueUSD | 57,022,000Source | 74,319,000Source | 69,764,000Source | 61,008,000Source |
| Selling, General and Administrative ExpenseUSD | 274,133,000Source | 252,193,000Source | 224,554,000Source | 179,581,000Source |
| Operating Income (Loss)USD | -91,713,000Source | -12,611,000Source | 28,097,000Source | 43,802,000Source |
| Other Nonoperating Income (Expense)USD | 2,253,000Source | 815,000Source | 448,000Source | 205,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -82,263,000Source | -9,052,000Source | 33,696,000Source | 45,552,000Source |
| Income Tax Expense (Benefit)USD | -1,815,000Source | 11,156,000Source | 12,349,000Source | 6,797,000Source |
| Net Income (Loss) Attributable to ParentUSD | -80,448,000Source | -20,208,000Source | 21,347,000Source | 38,755,000Source |
| Earnings Per Share, BasicUSD per share | -1.62Source | -0.41Source | 0.44Source | 0.81Source |
| Earnings Per Share, DilutedUSD per share | -1.62Source | -0.41Source | 0.43Source | 0.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 49,568,000Source | 49,125,000Source | 48,523,000Source | 47,987,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 49,568,000Source | 49,125,000Source | 49,427,000Source | 49,380,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 13,000Source | 28,000Source |
| Capitalized Computer Software, AmortizationUSD | 409,000Source | 0Source | 0Source | — |
| Current Income Tax Expense (Benefit)USD | 1,101,000Source | 7,566,000Source | 9,085,000Source | 8,141,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,603,000Source | -3,675,000Source | -1,909,000Source | -1,707,000Source |
| General and Administrative ExpenseUSD | 85,783,000Source | 89,898,000Source | 72,319,000Source | 54,742,000Source |
| Gross ProfitUSD | 182,420,000Source | 239,582,000Source | 252,651,000Source | 223,383,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -63,737,000Source | -52,859,000Source | -46,388,000Source | -25,366,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 4,594,000Source | 5,911,000Source | 6,986,000Source | 2,448,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 0Source |
| Nonoperating Income (Expense)USD | 9,450,000Source | 3,559,000Source | 5,599,000Source | 1,750,000Source |
| Operating Lease, ExpenseUSD | 3,570,000Source | — | — | — |
| Research and Development ExpenseUSD | 40,055,000Source | 53,973,000Source | 44,401,000Source | 35,983,000Source |
| Selling and Marketing ExpenseUSD | 102,528,000Source | 108,322,000Source | 107,834,000Source | 88,856,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 31,290,000Source | 28,618,000Source | 25,188,000Source | 22,252,000Source |
Filing attachments
staa-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 3 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 September 8, 2026 STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market LAKE FOREST, Calif.--(BUSINESS WIRE) -- STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®…
Read attachment ↗staa-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern LAKE FOREST, CA, [August 12, 2026] --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for …
Read attachment ↗staa-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 6 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 August 4, 2026 STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer Deborah Andrews appointed Executive Vice President and Chief Financial Officer LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extens…
Read attachment ↗staa-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter Net Sales of $93.5 million, highest first quarter Net Sales in Company’s history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern LAKE FOREST, CA, May 13, 2026 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in pha…
Read attachment ↗staa-ex99_1.htm · 8-K · 2026-04-08
EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026 LAKE FOREST, CA, April 8, 2026 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcemen…
Read attachment ↗staa-ex99_1.htm · 8-K · 2026-03-03
EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern LAKE FOREST, CA, March 3, 2026 --- STAAR Surgical Company (NASDAQ: ST…
Read attachment ↗